恒富控股(00643.HK)擬折讓約16.9%配發合共8180.4萬股 籌資約4810萬港元
格隆匯2月10日丨恒富控股(00643.HK)公佈,於2023年2月10日,公司與該等認購方訂立該等認購協議,據此,公司已有條件同意根據一般授權向該等認購方發行,而該等認購方已有條件同意以認購價每股認購股份0.59港元(較2月10日收市價每股股份0.71港元折讓約16.9%)認購認購股份,即合共8180.4萬股認購股份。
認購股份合共佔(i)公司於本公佈日期現有已發行股本約10.00%;及(ii)公司經配發及發行認購股份擴大後已發行股本約9.09%。
認購事項所得款項淨額預計約為4810萬港元,公司擬將其用於潛在合併及收購機會以及一般企業及營運資金用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.